{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:53:52Z","timestamp":1742399632854},"reference-count":24,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2021.0016","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T07:27:27Z","timestamp":1613546847000},"source":"Crossref","is-referenced-by-count":6,"title":["Gliflozins for the Treatment of Congestive Heart Failure and Renal Failure in Type 2 Diabetes"],"prefix":"10.3238","author":[{"given":"Anna Katharina","family":"Seoudy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik M.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Hollstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruwen","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingolf","family":"Cascorbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Laudes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"10.3238\/arztebl.m2021.0016_ref1","doi-asserted-by":"crossref","unstructured":"Nichols GA, Hillier TA, Erbey JR, Brown JB: Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24: 1614\u20139","DOI":"10.2337\/diacare.24.9.1614"},{"key":"10.3238\/arztebl.m2021.0016_ref2","doi-asserted-by":"crossref","unstructured":"Tuttle KR, Bakris GL, Bilous RW, et al.: Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014; 37: 2864\u201383","DOI":"10.2337\/dc14-1296"},{"key":"10.3238\/arztebl.m2021.0016_ref3","doi-asserted-by":"crossref","unstructured":"Brown E, Rajeev SP, Cuthbertson DJ, Wilding JPH: A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab 2019; 21 (Suppl 2): 9\u201318","DOI":"10.1111\/dom.13650"},{"key":"10.3238\/arztebl.m2021.0016_ref4","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117\u201328","DOI":"10.1056\/NEJMoa1504720"},{"key":"10.3238\/arztebl.m2021.0016_ref5","doi-asserted-by":"crossref","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644\u201357","DOI":"10.1056\/NEJMoa1611925"},{"key":"10.3238\/arztebl.m2021.0016_ref6","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347\u201357","DOI":"10.1056\/NEJMoa1812389"},{"key":"10.3238\/arztebl.m2021.0016_ref7","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al.: Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995\u20132008","DOI":"10.1056\/NEJMoa1911303"},{"key":"10.3238\/arztebl.m2021.0016_ref8","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, et al.: Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413\u201324","DOI":"10.1056\/NEJMoa2022190"},{"key":"10.3238\/arztebl.m2021.0016_ref9","doi-asserted-by":"crossref","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al.: SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396: 819\u201329","DOI":"10.1016\/S0140-6736(20)31824-9"},{"key":"10.3238\/arztebl.m2021.0016_ref10","doi-asserted-by":"crossref","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al.: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323\u201334","DOI":"10.1056\/NEJMoa1515920"},{"key":"10.3238\/arztebl.m2021.0016_ref11","doi-asserted-by":"crossref","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295\u2013306","DOI":"10.1056\/NEJMoa1811744"},{"key":"10.3238\/arztebl.m2021.0016_ref12","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al.: Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383: 1436\u201346","DOI":"10.1056\/NEJMoa2024816"},{"key":"10.3238\/arztebl.m2021.0016_ref13","doi-asserted-by":"crossref","unstructured":"Wilding J, Fernando K, Milne N, et al.: SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther 2018; 9: 1757\u201373","DOI":"10.1007\/s13300-018-0471-8"},{"key":"10.3238\/arztebl.m2021.0016_ref14","doi-asserted-by":"crossref","unstructured":"McMurray JJV, DeMets DL, Inzucchi SE, et al.: The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail 2019; 21: 1402\u201311","DOI":"10.1002\/ejhf.1548"},{"key":"10.3238\/arztebl.m2021.0016_ref15","doi-asserted-by":"crossref","unstructured":"Perreault L, Pan Q, Schroeder EB, et al.: Regression from prediabetes to normal glucose regulation and prevalence of microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes Care 2019; 42: 1809\u201315","DOI":"10.2337\/dc19-0244"},{"key":"10.3238\/arztebl.m2021.0016_ref16","doi-asserted-by":"crossref","unstructured":"McMurray JJ, Packer M, Desai AS, et al.: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993\u20131004","DOI":"10.1056\/NEJMoa1409077"},{"key":"10.3238\/arztebl.m2021.0016_ref17","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.: 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129\u2013200","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"10.3238\/arztebl.m2021.0016_ref18","doi-asserted-by":"crossref","unstructured":"Jackson AM, Dewan P, Anand IS, et al.: Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation 2020; 142: 1040\u201354","DOI":"10.1161\/CIRCULATIONAHA.120.047077"},{"key":"10.3238\/arztebl.m2021.0016_ref19","doi-asserted-by":"crossref","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al.: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255\u2013323","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"10.3238\/arztebl.m2021.0016_ref20","doi-asserted-by":"crossref","unstructured":"Verma S, McMurray JJV: SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 2018; 61: 2108\u201317","DOI":"10.1007\/s00125-018-4670-7"},{"key":"10.3238\/arztebl.m2021.0016_ref21","doi-asserted-by":"crossref","unstructured":"Cowie MR, Fisher M: SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 2020; 17: 761\u2013721","DOI":"10.1038\/s41569-020-0406-8"},{"key":"10.3238\/arztebl.m2021.0016_ref22","doi-asserted-by":"crossref","unstructured":"van Bommel EJM, Muskiet MHA, van Baar MJB, et al.: The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 2020; 97: 202\u201312","DOI":"10.1016\/j.kint.2019.09.013"},{"key":"10.3238\/arztebl.m2021.0016_ref23","doi-asserted-by":"crossref","unstructured":"Pereira MJ, Eriksson JW: Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs 2019; 79: 219\u201330","DOI":"10.1007\/s40265-019-1057-0"},{"key":"10.3238\/arztebl.m2021.0016_ref24","doi-asserted-by":"crossref","unstructured":"Kuwabara M, Niwa K, Hisatome I, et al.: Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. Hypertension 2017; 69: 1036\u201344","DOI":"10.1161\/HYPERTENSIONAHA.116.08998"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T09:37:16Z","timestamp":1638783436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":24,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2021.0016","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]}}}